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Open access undThe concept of radiation dose–volume effect has been exploited in breast cancer as boost treatment for
high risk patients and more recently in trials of Partial Breast Irradiation for low risk patients. However,
there appears to be paucity of published data on the dose–volume effect of irradiation on breast tissue
including the recently published report on Quantitative Analyses of Normal Tissue Effects in the Clinic
(QUANTEC). This systematic review looks at the current literature for relationship between irradiated
breast volume and normal tissue complications and introduces the concept of dose modulation.
 2012 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.The aim of radiation therapy is to deliver a tumouricidal dose
for optimal loco-regional control with relative sparing of the sur-
rounding normal tissues. The precise knowledge of tumouricidal
and tolerance doses to various tissues including dose–volume ef-
fect is necessary when using 3D-conformal and intensity modu-
lated radiotherapy techniques. Emami and colleagues [1] were
amongst the ﬁrst to publish a comprehensive review of radiation
tolerance for normal tissues, including quantiﬁcation of late nor-
mal tissue complication (NTC) as a function of volume of organ
irradiated. This review, although informative was limited by the
availability of few comprehensive databases, with most of the data
on dose–volume effect interpolated or extrapolated fromwhole or-
gan data, or based on the experience of the involved clinicians.
However it did provide a ﬁrm framework for quantifying the
volumetric and dosimetric measures which may inﬂuence normal
tissue complications. Since that publication, an update on the
dose–volume effect of radiation on the normal tissues has been
published in form of ‘‘Quantitative Analyses of Normal Tissue Ef-
fects in the Clinic (QUANTEC)’’ report [2]. This report helps in our
understanding of the normal tissue radiation tolerance and can
be utilised in clinical treatment planning as it provides an estimate
of the effect of change in irradiated volume on normal organ toler-
ance [3,4]. This information can be exploited by dose escalation to
the target volume with only a small amount of surrounding normalBox 193, Cambridge Univer-
bridge CB2 0QQ, UK.
okes.nhs.uk, drmukesh12@
er CC BY-NC-ND license.tissue receiving a higher dose. For example, the rectum is a critical
normal structure during dose escalation in prostate cancer radio-
therapy. Use of intensity modulated radiotherapy (IMRT) allows
safe dose escalation by reducing the volume of rectum receiving
high dose with favourable normal tissue complication rates com-
pared to 3D-conformal radiotherapy [5].
For years, the radiation dose–volume effect for the breast has
been exploited as boost treatment for breast cancer patients at
high risk of recurrence i.e. treating a small volume of breast tissue
to a higher dose (boost) to improve local control rates [6–8]. More
recently, breast dose–volume effect has been exploited in trials of
Partial Breast Irradiation (PBI) for patients at low risk of recur-
rence: the irradiated volume is conﬁned to the region around the
tumour bed with the aim of reducing toxicity whilst maintaining
local control rates. Despite there being very good evidence for a
radiation dose–volume effect in many organs including lung and
rectum, there appears to be a paucity of published data on dose–
volume effect of radiation on breast tissue. This systematic review
evaluates the evidence for a relationship between the volume of
breast tissue irradiated and the late NTCs including overall cosme-
sis, breast ﬁbrosis, breast induration and telangiectasia. It also
explores the hypothesis that a modest dose reduction to part of
the breast facilitates dose escalation to the tumour bed, with lower
than expected NTC.
Materials and methods
A systematic search was performed via Medline and Embase
with the search strategy ‘‘breast neoplasm’’ AND ‘‘radiotherapy
2 Radiation dose–volume effect on breast tissueOR irradiation’’. This was combined with ‘‘AND ﬁbrosis’’, ‘‘AND
cosme⁄’’, ‘‘AND side effect⁄’’, ‘‘AND toxicity’’, ‘‘AND shrinkage’’
and ‘‘AND normal tissue’’. The search was expanded to include re-
lated articles and a reference list of articles. The effects on NTC for
the following parameters are reported in this manuscript:
(a) Boost volume
(b) Partial Breast Irradiation (PBI)
(c) Fractionation regimens
Results
Impact of boost volume on normal tissue complications
EORTC 22881-10882 ‘‘boost versus no boost’’ trial (level I evidence)
The EORTC ‘‘boost versus no boost’’ trial randomised 5318 pa-
tients with early breast cancer between extra irradiation to the tu-
mour bed (boost of 16 Gy) versus no boost treatment after whole
breast irradiation (WBI) [6]. The boost was delivered using elec-
trons or tangential photon ﬁelds in daily fractionation of 2 Gy, or
with Iridium-192 implant at a dose rate of 0.5 Gy/h. At 10 years, re-
duced incidence of local recurrence was seen in the boost arm as
compared to the no boost arm (6.2% versus 10.2%; p < 0.0001).
However, an extra irradiation of 16 Gy to the tumour bed also in-
creased the rates of moderate to severe breast ﬁbrosis by 15% at
ten years (28.1% versus 13.2%; p < 0.0001). In this trial, 251 patients
with microscopically incomplete tumour excision were also ran-
domised to either a low dose boost of 10 Gy (126 patients) or a
high dose boost of 26 Gy (125 patients) [9]. The cumulative inci-
dence of moderate/severe ﬁbrosis for low dose and high dose boost
at ten years was 24% and 54%, respectively. Hence a dose escalation
of 16 Gy to the boost volume in the incomplete tumour excision
group increased the rates of moderate/severe ﬁbrosis by 30%, com-
pared with a 15% increase in the complete excision group for the
same 16 Gy increase in dose.
On review of the treatment protocol, the boost volume for com-
plete excision group was tumour bed plus 1.5 cm margin as com-
pared to tumour bed plus 3 cm margin in the incomplete tumour
excision group. It demonstrates that an increase in irradiated
breast volume in the incomplete excision group doubled the risk
of moderate/severe ﬁbrosis for the same dose escalation of 16 Gy,
supporting a dose–volume relationship for breast tissue. Further-
more, Collette et al. [10] reported on factors predicting the risk of
breast ﬁbrosis at ten years. The boost volume was associated with
an increased risk of moderate or severe ﬁbrosis in univariate anal-
ysis. Vrieling et al. [11] from the same group had previously re-
ported worse cosmetic outcome in patients with boost volume
>200 cm3 as compared to 6200 cm3 (odds ratio 0.47 95%CI 0.29–
0.76; p = 0.002) in univariate analysis after three years of follow
up. However, boost volume was not a signiﬁcant variable affecting
ﬁbrosis and cosmesis in multivariate analysis.
Brachytherapy boost (level IV evidence)
Borger et al. [12] reported on the dose and volume effect on
breast ﬁbrosis after using brachytherapy boost. Four hundred and
four patients were treated with external bream radiotherapy,
50 Gy in 2 Gy daily fractions to the whole breast, followed by an
iridium implant boost (dose rate 0.57 ± 0.11 Gy/h) of 15 Gy (101
patients), 25 Gy (301 patients) and 20 Gy (2 patients). At a median
follow up of 70 months, a fourfold higher risk of ﬁbrosis was ob-
served for each 100 cm3 increase in irradiated boost volume, and
a tenfold higher risk of ﬁbrosis was observed when the total dose
exceeded 79 Gy compared to doses below 70 Gy.
McRae and colleagues from Georgetown University Medical
Centre reported on the relationship between brachytherapy boost
volume and soft tissue complication in 1987 [13]. Retrospectivebrachytherapy plans for 5 patients with radiation induced soft tis-
sue damage were compared to 51 patients who experienced no se-
vere complication after breast conserving surgery (BCS) and WBI
followed by Iridium-192 boost. The mean boost volume for pa-
tients who developed soft tissue damage was signiﬁcantly higher
for all dose levels between 10 Gy and 50 Gy when compared to pa-
tients with no reported complications (p < 0.05), suggesting a vol-
ume–NTC relationship at any speciﬁc dose.
Olivotto et al. [14] also reported an association between the vol-
ume of brachytherapy boost and late cosmetic outcome. Five hun-
dred and ninety-three patients received breast-conserving surgery
followed by WBI (46–50 Gy over 4.5–5 weeks). Four hundred and
ninety-seven patients received low dose rate Iridium-192 implant
boost to bring the tumour bed dose to 60 Gy. At a median follow up
of 76 months, the volume of boost, measured by the number of
Iridium seeds used, was a signiﬁcant factor for fair/poor cosmesis.
Patients with <70 seeds had a 15% risk of fair/poor cosmesis com-
pared to 38% for patients containingP100 seeds (p < 0.01). The use
of greater number of seeds would imply a larger volume of irradi-
ated breast tissue, indicating towards a radiation volume effect on
cosmesis. Several other single and multi-centre studies have re-
ported on the relationship between volume of brachytherapy boost
and NTC risk and are summarised in Table 1.
Intra-operative RT (IORT) boost using low energy X-ray (level IV
evidence)
IORT using low energy X-ray of 50 kV can be used to deliver a
single fraction of high dose radiation boost to the tumour bed after
lumpectomy. Advocates for IORT cite several potential advantages
of using this approach: delivery of radiation immediately after
surgery prevents tumour cell proliferation; change in cytokines
pattern into a less stimulating microenvironment, which is postu-
lated to decrease local recurrence rates; and reduced risk of geo-
graphical miss [15,16].
The University of Heidelberg, Germany reported on the late tox-
icity data (at 3 years) for 79 cases treated with this approach [17].
All patients received 20 Gy intra-operative boost using 50 kv X-ray
followed by 46–50 Gy in 2 Gy daily fraction of WBI ± supra/infra-
clavicular fossa irradiation. Thirty-ﬁve percent patients developed
grade 2–3 breast ﬁbrosis. They observed the applicator size for
IORT signiﬁcantly correlated with late breast ﬁbrosis (spearman
rank correlation coefﬁcient 0.496, p < 0.001). A larger applicator
size would imply a larger volume of irradiated breast tissue sug-
gesting a radiation volume effect on late normal tissue toxicity.
Cobalt unit based boost (level IV evidence)
Dewar et al. [18] reported on the Institute Gustave-Roussy
experience for cosmetic outcome after breast-conserving surgery
and radiotherapy. Five hundred and ninety-two patients received
WBI (45 Gy in 2.5 Gy per fraction, four times weekly) using two
tangential ﬁelds, each ﬁeld treated on alternate days followed by
tumour bed boost of 15 Gy in 6 fractions using one-two ﬁelds on
the cobalt unit. In addition to applied dose per fraction, the area
of ﬁeld to the tumour bed (>30 cm3) was associated with an in-
creased risk of ﬁbrosis (p < 0.02) and telangiectasia (p < 0.01) in
multivariate analysis.
Other studies (level IV evidence)
The Fox Chase Cancer Center, Philadelphia recently reported on
tumour bed boost parameters associated with overall cosmesis and
ﬁbrosis for 3186 patients treated at their centre from 1970–2008
[19]. All patients received whole breast irradiation (46–50 Gy)
followed by a tumour bed boost of 10–18 Gy using electrons or pho-
tons. With a median follow up of 78 months, smaller boost cut-out
size was a borderline predictor of excellent cosmesis (p = 0.05) and
lower risk of breast ﬁbrosis (p < 0.0001) on univariate analysis.
Table 1
Effect of brachytherapy boost volume to NTC.
First author, Institute and radiation
technique
Number of
patients
(median follow
up)
TNM/
stage
Comments on NTC assessment Results
Borger et. al. [12]
Netherlands Cancer Institute
WBI 50 Gy in 25 fractions over 5 weeks
followed by low dose rate Iridium
implant boost of 15 Gy (101 pts), 25 Gy
(301 pts) and 20 Gy (2 pts)
404 patients
median follow
up 70 months
(range 30–
133 months)
Stage
1–2
Four trained physicians scored ﬁbrosis by
palpating induration in the tumour bed.
Four-scale scoring system: no ﬁbrosis = no
difference in consistency between the two
breasts, grade 1 = a small difference, grade
2 = a moderate difference, grade 3 = a large
difference. The scores of the four
investigators were averaged to obtain the
ﬁnal result per patient
Implant volume (100% dose) associated with
risk of ﬁbrosis Odds ratio 4.2 (95% CI 2.3–8.0)
per 100 cm3 increase in boost volume
McRae et al. [13]
Georgetown University Medical Centre,
Washington
WBI 50 Gy in 25 fractions over 5 weeks
using Cobalt followed by low dose rate
Iridium 192 boost of 20 Gy
56 patients with
a minimum
follow up of
2.5 years
Stage
1–3
Radiation injury to connective tissue or fat
necrosis requiring prolonged medical or
surgical management
Mean boost volume signiﬁcantly higher for
all dose level between 10 Gy and 50 Gy for
patients who developed soft tissue damage as
compare to patients with no reported
complications (p < 0.05)
Dewar et. al. [18]
Institut Gustave-Roussy, France
WBI 45 Gy in 2.5 Gy per fraction using
two tangential ﬁelds followed by
tumour bed boost of 15 Gy in 6
fractions using one to two ﬁelds on the
cobalt unit
592 patients
mean follow up
78 months
(standard
deviation
35 months)
T1-2
N0-1
Fibrosis and/or telangiectasia of the whole
breast/the tumour bed graded as absent,
slight, moderate or severe by the radiation
oncologist. Cosmetic outcome graded as
excellent, good, fair and poor
Area of ﬁeld to the tumour bed (>30 cm3)
associated with increased risk of ﬁbrosis
(p < 0.02) and telangiectasia (p < 0.01) on
multivariate analysis. No relationship
between cosmesis and area of ﬁeld to the
tumour bed
Olivotto et al. [14]
Joint Center for Radiation Therapy,
Boston
WBI 46–50 Gy in 4.5–5 weeks,
followed by low dose rate Iridium-192
boost (10–27 Gy)
497/593 with
Iridium-192
boost
Median follow
up 76 months
(range 37–
186 months)
T1-2
N0-1
Overall cosmesis scored as excellent, good,
fair or poor by the physician. Excellent if
treated breast looked the same as the
opposite breast, good if minimal but
identiﬁable effects of radiation, fair when
signiﬁcant effects of radiation and a poor if
severe normal tissue sequelae
Boost volume measured by number of
Iridium-192 seeds associated with increased
risk of fair/poor cosmesis (p < 0.0001 for
trend)
Clarke et. al. [57]
Paul A. Bissinger Memorial Center for
Radiation Therapy, Stanford
WBI 45–55 Gy in 1.8–2.5 Gy per
fraction followed by low dose rate
Iridium-192 boost (18–25 Gy)
64/78 patients
with Iridium
192 boost
Median follow
up 42 months
(range 30–
120 months)
Stage
1–2
Cosmetic result scored as excellent (treated
breast looked the same as the opposite
breast), satisfactory (mild to moderate breast
asymmetry with <l/3 volume loss secondary
to surgery or retraction from ﬁbrosis) or
unsatisfactory (marked breast asymmetry or
severe ﬁbrosis with >1/3 volume loss).
Breast ﬁbrosis scored as mild, moderate or
severe.
6% patients developed moderate/severe
ﬁbrosis with no correlation between ﬁbrosis
and implanted boost volume. Surgical factors
like poorly planned excision scar and large
volume excision main factors for
unsatisfactory cosmesis.
Wazer et. al. [58]
Tufts University School of Medicine,
Boston
WBI 50 to 50.4 Gy at 1.8–2 Gy per
fraction followed by low dose rate
Iridium-192 boost of 20 Gy
127 patients
Median follow
up 80 months
(standard
deviation
34 months)
Stage
1–2
Cosmetic score scored by two separate
examiners as excellent = perfect symmetry
and no visible distortion, good = slight
distortion, visible telangiectasia or absent
nipple-areolar complex, fair = moderate
distortion, hyper pigmentation, prominent
skin retraction, oedema or telangiectasia and
poor = marked distortion, oedema, ﬁbrosis,
severe hyper-pigmentation. The lowest score
was used
No correlation between implant volume and
cosmetic score.
Wronczewska et. al. [68]
Nicolaus Copernicus University, Poland
WBI 50–50.4 Gy in 1–8-2 Gy fraction
followed by high dose rate Iridium-192
boost of 5–20 Gy
54 patients
Mean follow up
65 months
(range 41–
89 months)
Cosmesis and breast ﬁbrosis assessed by two
doctors independently and compared to the
contralateral breast
Boost volume receiving 100% (V100) was
signiﬁcantly associated with risk of breast
ﬁbrosis (p = 0.0236)
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cantly associated with higher ﬁeld size on multivariate analysis.Partial Breast Irradiation (PBI)
Randomised controlled trials of Partial Breast Irradiation (PBI) versus
whole breast irradiation (WBI) (level I evidence)
WBI is the current standard of care after breast-conserving sur-
gery and the latest Early Breast Cancer Trialist Collaborative Group
(EBCTG) systematic review conﬁrmed an absolute 5% reduction in
15 year breast cancer mortality using WBI [20]. In the last decade,
PBI has been explored as an alternative to WBI in low risk patients.
PBI involves irradiation of a limited volume of breast tissue aroundthe tumour bed and is currently under investigation in several ran-
domised phase II and III trials (Table 2). It is based on the rationale
that the majority of local recurrences are located close to the area
of surgical resection/index quadrant, foci of breast disease outside
the index quadrant are often new primary tumours [21,22] and
irradiating a limited volume of breast would reduce treatment re-
lated morbidity. To date, four randomised controlled trials (RCT)
comparing WBI versus PBI have reported on their outcome.
The Christie group were the ﬁrst to report in 1993 [23]. They
randomised 708 patients with breast cancer 64 cm in diameter
to PBI or WBI plus regional lymph nodes irradiation. PBI involved
tumour bed irradiation (average ﬁeld size 8 cm  6 cm) to
40–42.5 Gy in 8 fractions over 10 days using electrons and WBI
Table 2
Phase II–III randomised controlled trials comparing WBI versus PBI.
Trial/institute Control arm (WBI) Test arms (PBI): treatment modality Median
follow up
(months)
Target
accrual
Reported
Christie group
trial [23]
WBI 40 Gy in 15 fractions with matched
ﬁeld for regional nodes
PBI: 40–42.5 Gy in 8 fractions using electrons 65 months 708 Yes
Yorkshire Breast
Cancer Group
trial [24]
WBI 40 Gy in 15 fractions with 15 Gy
boost
PBI using direct cobalt, caesium or electrons beam or a small
mega-voltage tangential pair to a dose of 55 Gy in 20 fractions
96 months 174
(pre-
mature
closure)
Yes
Hungarian
National
Institute of
Oncology [25]
WBI using Cobalt or photons beam to a
dose of 50 Gy in 25 fractions over
5 weeks
HDR Iridium-192 (85 pts) to a dose of 36.4 Gy in 7 fractions over
4 days or Electrons (40 pts) to a dose of 50 Gy in 25 fractions
prescribed to the 80% isodose
66 258 Yes
TARGIT [26] WBI 40–56 Gy with optional boost of
10–16 Gy
PBI: 20 Gy single fraction using Intra-operative 50 kV photons 24 months 2232 Yes
ELIOT [69] WBI 50 Gy in 25 fractions with 10 Gy
boost
PBI: Intra-operative electrons 21 Gy in single fraction NA 1300
(closed
2007)
No
IMPORT LOW
[49,50]
WBI 40 Gy in 15 fractions, no boost Arm 1: 36 Gy in 15 fractions to the low risk volume of the breast
and 40 Gy in 15 fractions to the index quadrantArm2 (PBI):
40 Gy in 15 fractions over 3 weeks to the index quadrant only
NA 2000
(closed
2010)
No
GEC-ESTRO [70] WBI 50–50.4 Gy in 25–28 fractions with
10 Gy optional boost
PBI: 32 Gy in 8 fractions or 30.3 Gy in 7 fractions HDR or 50 Gy
PDR
NA 1170
(activated
2004)
No
NSABP-39 [71] WBI 50–50.4 Gy in 25–28 fractions with
10–16 Gy optional boost
PBI: 34 Gy in 10 fractions over ﬁve days using single/multi-
source brachytherapy or 38.5 Gy in 10 fractions over 5 days
using 3D-CRT
NA 4300
(activated
2005)
No
RAPID [72] WBI 42.5 Gy in 16 fractions with
optional 10 Gy boost
PBI: 38.5 Gy in 10 fractions BD over 5–8 days using 3D-CRT NA 2128
(activated
2006)
No
IRMA [73] WBI 45 Gy in 18 fractions or 50 Gy in 25
fractions or 50.4 Gy in 28 fractions with
optional 10 – 16 Gy boost
PBI: 38.5 Gy in 10 fractions BD over 5 days using 3D-CRT NA 3302
(activated
2007)
No
Danish Breast
Cancer Co-
operative
Group [51]
WBI 40 Gy in 15 fraction PBI: 40 Gy in 15 fraction using 3D-CRT NA 628
(activated
2009)
No
SHARE [74] WBI 50 Gy in 25 fractions + 16 Gy boost
or WBI 40–42.5 Gy in 15–16 fractions
without boost
PBI: 40 Gy in 10 fractions BD over 5 to 7 days using 3D-CRT NA 2796
(activated
2010)
No
WBI: whole breast irradiation; PBI: Partial Breast Irradiation; HDR: high dose rate; PDR: pulsed dose rate; LDR: low dose rate; 3D-CRT: 3-dimensional conformal radio-
therapy; NA: not applicable.
4 Radiation dose–volume effect on breast tissueinvolved treating the whole breast to 40 Gy in 15 fractions over
21 days using a tangential pair with matched ﬁeld for regional
nodes. After a median follow up of 65 months, recurrence rates
were higher in the PBI arm as compare to WBI arm (19.6% versus
11%; p = 0.0008). The possible reasons for higher recurrence rates
in the PBI armwere difﬁculty in deﬁning the target volume, leading
to geographical miss and including patients with inﬁltrating lobu-
lar carcinoma and ductal carcinoma with an extensive intra-ductal
component. Patients with PBI also had signiﬁcantly higher rates of
marked breast ﬁbrosis (14% versus 5%) and telangiectasia (33% ver-
sus 12%) when compared to WBI.
The Yorkshire Breast Cancer Group randomised 174 patients
between WBI (40 Gy in 15 fractions over 21 days) followed by
tumour bed boost (15 Gy in 5 fractions) and PBI using a variety
of techniques, including a direct cobalt or caesium beams, elec-
trons or a small mega-voltage tangential pair to a dose of 55 Gy
in 20 fractions over 28 days [24]. The trial closed prematurely
due to poor accrual with higher loco-regional recurrence rates in
the PBI group as compared to the WBI group (24% versus 9%). It
has been suggested that higher recurrence in the PBI arm was
secondary to difﬁculty in accurate deﬁnition of the target volume
(tumour bed). Treatment related morbidity with PBI and WBI has
not been reported. Both these trials pioneered the concept of PBI
at a time when patient selection and tumour bed localisation
was at an early stage of development. Subsequent randomised
trials have used more stringent protocols for both of these factors.The Hungarian National Institute of Oncology PBI trial [25] and
TARGIT trial [26] have more recently reported their outcomes. The
Hungarian PBI trial randomised 258 patients with T1 N0-1 grade
62 breast cancer to WBI or PBI after breast-conserving surgery
[25]. WBI was delivered using Cobalt or photon beams to a dose
of 50 Gy in 2 Gy daily fractions and PBI was delivered using high
dose rate (HDR) Iridium-192 brachytherapy (85 pts) to a dose of
36.4 Gy in 5.2 Gy per fraction over 4 days or electrons (40 pts) to
a dose of 50 Gy in 2 Gy daily fractions prescribed to the 80% iso-
dose. At a median follow up of 66 months (range 18–101 months),
the local recurrence rates were not signiﬁcantly different in the
two trial arms. The cosmetic results using Harvard criteria [27]
were favourable in the PBI arm. The rate of excellent to good cos-
mesis was 77.6% for the PBI group and 62.9% for the WBI group
(p = 0.009).
The TARGIT-A trial randomised 2232 patients with early breast
cancer to WBI (40–56 Gy) ± a boost of 10–16 Gy and intra-opera-
tive PBI using low energy X-rays (50 kV) to a dose of 20 Gy to
the tumour bed attenuating to 5–7 Gy at 1 cm depth [26]. Patients
with adverse histological features including invasive lobular carci-
noma or an extensive intra-ductal component also received WBI
without boost in the PBI arm. At two years, the local recurrence
rate was similar with no signiﬁcant difference in the rate of toxic-
ity, but the type of toxicity was signiﬁcantly different in both arms.
WBI arm had higher RTOG grade 3–4 toxicity for dermatitis, telan-
giectasia or breast pain (2.1% versus 0.5%; p = 0.002). In contrast,
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trum of side effects. Breast seroma needing more than three aspi-
rations was more common in the intra-operative PBI group (2.1%
versus 0.8%; p = 0.012) and more patients reported skin breakdown
or delayed healing, required surgical evacuation of haematoma and
intravenous antibiotics or surgical intervention for infection. The
cosmetic results have not been reported.
Case-matched pair studies (level III evidence)
Four case match pair studies have also compared normal tissue
complications between partial and whole breast irradiation after
BCS. Polgar et al. [28] prospectively selected 45 patients with
T1N0-1 breast cancer treated with PBI using HDR Iridium-192 im-
plants to a dose of 30.3–36.4 Gy in 7 fractions over 4 days and
matched 80 patients (eligible for PBI) treated with WBI 50 Gy in
2 Gy daily fractions with or without a tumour bed boost of 10–
16 Gy. At a median follow up of 7 years, the ipsilateral breast recur-
rence rates were not signiﬁcantly different in the two groups.
Excellent/good cosmesis using Harvard criteria [27] was seen in
84.4% patients in the PBI arm and 68.3% patients in the WBI arm
(p = 0.04). However, a trend of increased incidence of RTOG grade
2–3 ﬁbrosis was seen in the PBI group as compare to WBI group
without boost (20% versus 5.8%; p = 0.06).
The William Beaumont group matched 174 patients treated
with PBI (low dose rate Iodine-125 implant, 50 Gy over 96 h, dose
rate of 0.52 Gy/h or HDR implant 32 Gy in 8 fractions, each sepa-
rated by 6 h), with 174 patients treated with WBI with a median
total dose of 60 Gy to the tumour bed [29]. With 36 months follow
up, cosmetic outcome was more favourable in the PBI group as
compared to the WBI group (excellent/good cosmesis 90% versus
83%; p = 0.17), although this was not statistically signiﬁcant.
King et al. [30] matched 51 patients treated with PBI (low dose
rate Iridium-192 implant 45 Gy over 4 days or HDR implant 32 Gy
in 8 fractions over 4 days) with 94 patients treated with WBI to a
mean dose of 59 Gy after breast-conserving surgery. A blinded pa-
nel of healthcare professionals scored cosmesis on a four-part scale
(excellent, good, fair, poor) after reviewing photographic slides. At
20 months follow up, 75% patients in the PBI group and 84% pa-
tients with WBI had excellent/good cosmesis (p = not signiﬁcant).
Grade I and II treatment complications including skin erythema,
desquamation, discoloration, hyperpigmentation, dimpling; breast
pain, tenderness, shrinkage or ﬁbrosis were signiﬁcantly more
common with WBI than PBI (80% versus 22%, p = 0.001). Grade III
treatment complications requiring surgical intervention were not
signiﬁcantly different in the two groups (8% versus 5%, p = not
signiﬁcant).
Tata Memorial Hospital, India matched 27 patients treated with
PBI using HDR brachytherapy 34 Gy in 10 fractions over 6–8 days
with 67 patients treated with WBI (45 Gy in 25# over 5 weeks fol-
lowed by a tumour bed boost using electrons 15 Gy in 6 fractions
or interstitial HDR brachytherapy with a single 10 Gy fraction
[31]. At a median follow up of 43 months, cosmetic outcome was
superior in the PBI group as compare to the WBI group (excel-
lent/good cosmesis 88.9% versus 56%; p = 0.003). No signiﬁcant dif-
ference was seen in the rates of moderate/severe breast ﬁbrosis.
Effect of treatment volume on NTC in PBI series
There are several publications reporting on the efﬁcacy and low
toxicity using PBI with only a few evaluating the impact of treat-
ment volume on NTC. The current literature on the volume effect
of PBI for 3D-CRT/IMRT, electrons and single/multi-source brachy-
therapy is summarised below.
3D-CRT/IMRT based PBI (level IV evidence)
Jagsi et al. [32] reported on the cosmetic outcome of 32 patients
treated with PBI using IMRT at deep inspiration breath hold. Allpatients received 38.5 Gy twice daily fractionation over ﬁve con-
secutive days. At a median follow up of 2.5 years, 22% patients
were scored as unacceptable cosmesis. Retrospective comparison
between patients with acceptable and unacceptable cosmesis
showed the mean proportion of breast volume receiving a mini-
mum of 100% of the prescribed dose i.e. 38.5 Gy (V100) was lower
in patients with acceptable cosmesis as compare to patients with
unacceptable cosmesis (15.5% versus 23.0%; p = 0.02). The mean
proportion of breast volume receiving a minimum of 50% of the
prescribed dose i.e. 19.25 Gy (V50) was also smaller in the accept-
able cosmesis group as compare to unacceptable cosmesis
(p = 0.02).
Hepel et al. [33] also reported on a positive correlation between
the volume of breast tissue treated with PBI and overall cosmesis.
Sixty patients received PBI to a dose of 38.5 Gy twice daily fraction-
ation over one week using 3D-CRT. At a median follow up of
15 months, 18% patients developed fair-poor cosmesis and 25%
developed grade 2–4 subcutaneous ﬁbrosis. In univariate analysis,
the size of 3D-CRT target volume in proportion to the overall breast
volume (PTV_Eval/WBV) correlated with fair/poor cosmesis
(p = 0.02) and grade 2–4 subcutaneous ﬁbrosis (p = 0.10). These
two publications suggested an association between breast volume
irradiated in PBI and normal tissue complications.
In contrast, Chen and colleagues from the William Beaumont
group reported no association between overall cosmesis and
PTV_Eval/WBV [34,35]. Ninety-four patients received PBI to a dose
of 38.5 Gy twice daily fractionation over ﬁve consecutive days
using 3D-CRT. Of the 56 patients with cosmesis assessment of
P48 months, 11% patients had fair to poor cosmesis and 3% pa-
tients had grade 3 ﬁbrosis with no association between cosmesis/
subcutaneous toxicity and PTV_Eval volume.
Single source brachytherapy/multi-source brachytherapy (level IV
evidence)
Multi-source brachytherapy has been used for PBI for many
years with most publications focusing on local control rates and
limited reporting of normal tissue toxicity. Some have reported
on factors associated with normal tissue toxicity and have com-
mented on a positive correlation between NTC and the implant vol-
ume. Yeo et al. [36] reported on the efﬁcacy and safety of PBI using
multi-source brachytherapy for 48 patients with a median follow
up of 53 months. A dose of 34 Gy in 10 fractions over ﬁve days
was delivered to the tumour bed plus a 1–2 cm margin. Fourteen
percent patients developed grade 2 subcutaneous toxicity with
V100 and V150 signiﬁcantly higher in these patients (p = 0.018
and 0.034, respectively). No patient had poor cosmesis.
Wazer et al. [37] reported on the variables associated with late
toxicity and long term cosmetic outcome after multi-source brach-
ytherapy PBI using pooled data from Tufts University, Brown Uni-
versity and Virginia Commonwealth University. The data for 75
patients with a median follow up of 6 years were analysed. The
number of dwell positions (i.e. total volume of implanted breast
tissue) correlated with late cosmetic outcome (p = 0.04). Lawenda
and colleagues reported no association between implant volume
and overall cosmetic outcome for 48 patients treated with low
dose rate brachytherapy at their centre from 1997–2001 [38].
The purpose of the study was to evaluate dose escalation in PBI
and the total dose was escalated in three groups of 50 Gy, 55 Gy
and 60 Gy and implant volume was divided into four groups. A
non signiﬁcant trend between dose escalation and ﬁbrosis was
seen but they also observed a decline in the incidence of breast
ﬁbrosis with increase in implant volume, a ﬁnding contrary to cur-
rent published literature.
The Mammosite single source brachytherapy device (Hologic
Inc., Medford MA, USA) has been used for PBI since approval by
the FDA in 2002. Many groups have reported on its efﬁcacy with
6 Radiation dose–volume effect on breast tissueconﬂicting reports on the correlation between balloon volume and
overall cosmesis/ﬁbrosis [39–43]. The American Society of Breast
Surgeons Mammosite Breast Brachytherapy registry trial is the big-
gest series published to date [44]. The series reported on factors
associated with optimal cosmetic outcome and includes 1440 pa-
tients with a median follow up of 43 months. On multiple regres-
sion analysis, the balloon ﬁlling volume was not a signiﬁcant
variable affecting cosmesis (p = 0.085). Breast related wound infec-
tion and balloon to skin distance were found to be the most impor-
tant variables affecting cosmesis.Breast fractionation studies
The Royal Marsden Hospital and Gloucestershire Oncology Cen-
tre (RMH/GOC) trial [45] randomised 1410 patients with early
breast cancer into three WBI regimens. The control arm consisted
of 50 Gy in 25 fractions over 5 weeks. The two test arms were (1)
39 Gy in 13 fractions over 5 weeks and (2) 42.9 Gy in 13 fractions
over 5 weeks, respectively. The equivalent dose in 2 Gy fractions
(EQD2) using a a/b ratio of 3.1 Gy for palpable breast induration,
are 46.7 Gy and 53.8 Gy for test arms 1 and 2, respectively. The risk
of moderate to severe induration at 10 years between Arm 1 and 2
was 27% and 51%, respectively suggesting a 24% increased risk of
induration with a dose escalation of 7 Gy to the whole breast
(3.3% increase per Gy). Compared to this fractionation effect, an
escalated dose to tumour bed alone i.e. boost of 15.5 Gy in 7 frac-
tions (EQD2 of 16 Gy) increased the risk of induration by 17%
(1.05% increase per Gy). These data indicate a radiation volume-ef-
fect for breast tissue, as the effect of induration per Gy of radiation
increases with breast volume irradiated.Discussion
With the increasing use of CT planning, Partial Breast Irradiation
techniques, simultaneous boost techniques and dose escalation
studies, a better understanding of the dose–volume relationship
for breast tissue is required. The current literature suggests that
volumetric parameters affect NTC, although it is poorly quantiﬁed
with some conﬂicting clinical results.
This overview faces several challenges. The late normal tissue
toxicity post radiotherapy is inﬂuenced by several patient and
treatment related factors (Table 3). These parameters were vari-
able in the identiﬁed studies. A variety of treatment approaches
have been used including photons, electrons, intra-operative tech-
niques and brachytherapy. In addition, the reported studies have
used different endpoints (ﬁbrosis, cosmesis and telangiectasia)Table 3
Patient and treatment factors associated with late normal tissue complications.
Patient factors Surgical factors Othe
Increasing age [56,75] Large excision volume [11,14,76] Tota
Smoking [53,75] Post operative complications including haematoma,
seroma or infection [10,11,53]
Radi
[10,5
Large breast size
[53,56,57,82–84]
Axillary dissection [48,76] Tum
Tumour location
[11,48]
Boos
Genetic variation
[47,85]
Boos
brac
Nod
Dose
[87,8
Hyp
inhowith several different scoring methods and a diverse period of
follow up. These challenges make it difﬁcult to draw ﬁrm conclu-
sions on the qualitative and quantitative effect of dose–volume
relationship for breast tissue. Some studies have also used bra size
and chest wall separation as a surrogate for breast size. These
methods though useful can have inherent inconsistency; pre-oper-
ative bra size may not reﬂect the true post-operative breast volume
and chest wall separation only provide 2-dimensional information
of the breast and may not necessarily represent volume of breast
above or below the central axis. Breast volume in cm3 or ml should
be a preferred method for reporting breast size.
The study by Borger et al. [12] using low dose rate iridium im-
plants provides the most robust quantitative data on the dose–vol-
ume relationship. Seven independent factors were associated with
breast ﬁbrosis: old age, long follow up, clinical tumour size, cobalt-
60 beam irradiation, total dose, implant volume and chemother-
apy. For every 100 cm3 increase in irradiated boost volume, the risk
of ﬁbrosis increase four-fold and a two fold increase in boost vol-
ume will result in an 11% decrease in tolerance dose (NTD50). It
is however difﬁcult to be certain as to how the low dose rate brach-
ytherapy data can be extrapolated to HDR brachytherapy, electron
and photon boost techniques. The RMH/GOC trial [45] which used
electron boost provides indirect quantitative information on the
dose–volume relationship for NTC. For every Gy increase in boost
dose, the risk of moderate to severe breast induration increases
by 1% as compared to 3% when the whole breast dose is increased
by one Gy.
The EORTC boost trials [6,9] also provided quantitative informa-
tion on the volumetric effect where increasing the tumour bed
margin from 1.5 cm to 3 cm doubles the rates of moderate/severe
ﬁbrosis from 15% to 30%. However, it is possible that the increase
in NTC is secondary to a combination of larger boost volume and
a steeper dose–response curve as total dose increased up to
76 Gy in the incomplete excision group. The EORTC boost trial also
reported boost volume as a predictor of moderate/severe ﬁbrosis
and worse cosmesis in univariate analysis but not in multivariate
analysis. There are several possible explanations for this: (1) There
is no true independent volumetric effect. (2) Other factors such as
total surgical excision volume, post-operative complications, con-
comitant chemotherapy, quality of radiation and boost treatment
were more dominant variables affecting NTC when compared to
the boost volume. (3) Total boost volume was dependent on the
boost technique, with the smallest boost volume for interstitial
technique (60 cm3), more than twice the volume with electron
boost (144 cm3) and nearly ﬁve times as large with photon boost
(288 cm3) [46]. The rate of ﬁbrosis was similar despite a consider-
able smaller treatment volume using interstitial brachytherapy. Itr radiotherapy factors Chemotherapy factors
l dose [12,47,48,56] Timing of chemotherapy: concomitant or
sequential [56,77–79]
otherapy quality and technique
6]
Type of chemotherapy [80,81]
our bed Boost [6]
t dose [9]
t technique: electron, photon or
hytherapy [19,86]
al irradiation [48,79]
inhomogeneity (double trouble)
8]
ofractionation and dose
mogeneity (triple trouble) [88]
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(which may lead to increased ﬁbrosis) is neutralised by a smaller
treatment volume. A direct comparison of boost volume using dif-
ferent boost techniques is not practical.
Randomised controlled trials including the Hungarian PBI trial
[25] and TARGIT trial [26] provides a strong qualitative indication
on a volume–NTC relationship. They report superior cosmetic out-
come and reduced NTC rate in the PBI arm when compared to the
WBI. However, these are signiﬁcant differences in the radiotherapy
techniques and fractionation schedules between the two groups,
making it difﬁcult to draw conclusions on the radiation volume ef-
fect on breast tissue. The other reported randomised trial from
Christie had reported a higher rate of breast ﬁbrosis and telangiec-
tasia in the WBI arm [23]. A dose–response relationship for late
radiation effects including telangiectasia and breast ﬁbrosis is well
established [6,47,48] and these dissimilar results can possibly be
explained by calculating the 2 Gy equivalent dose (EQD2) for the
PBI and WBI groups using an a/b ratio of 3.1 [45] for ﬁbrosis. The
WBI group had received a lower dose of 45 Gy EQD2, compared
to 63–70 Gy for the PBI group in the Christie trial.
The four matched case series [28–31] comparing PBI and WBI
also showed favourable cosmesis and lower NTC risk with PBI ex-
cept for higher grade 2–3 ﬁbrosis in the Hungarian series [28]. It is
possible that signiﬁcant dose heterogeneity with the mean dose
non uniformity ratio of 0.45 using Iridium-192 implants could ex-
plain the increased grade 2–3 ﬁbrosis in the PBI arm in the Hungar-
ian series. These case series are a retrospective analysis with a
small number of patients and other factors known to inﬂuence
NTC including breast volume, post-surgical cosmesis, boost radia-
tion, chemotherapy and smoking are not considered. Also, similar
to the randomised trials, they evaluated PBI and WBI using differ-
ent radiotherapy techniques and fractionation.
IMPORT LOW trial and The Danish Breast Cancer Cooperative
Group trial (not reported) are two of the few randomised trials
comparing Partial Breast Irradiation (PBI) versus whole breast irra-
diation (WBI) with volume of breast irradiated as the solitary ran-
domisation variable. IMPORT LOW is a randomised Phase 3 trial
comparing WBI with two dose level of PBI delivered using IMRT
in women with low risk breast cancer and has completed target ac-
crual of 2000 patients in 2010 [49,50]. The control arm (WBI) deliv-
ers 40 Gy in 15 fractions over 3 weeks to the whole breast. Arm 1
delivers synchronous 40 Gy in 15 fractions to the partial breast PTV
and 36 Gy in 15 fractions to the remainder of the whole breast.
Arm 2 (PBI) delivers 40 Gy in 15 fractions to the partial breast
PTV alone (Supplementary material-Fig. 1). The primary endpoint
is local tumour control in the ipsilateral breast and the secondary
endpoints include location of tumour relapse, contralateral pri-
mary tumours, regional and distant metastases, late adverse effects
in normal tissues, quality of life (QOL) and economic evaluation.
The Danish Breast Cancer Cooperative Group trial is a Phase 2
study comparing PBI to WBI in low risk breast cancer patients with
both treatment arms receiving 40 Gy in 15 fractions over 3 weeks
[51]. The primary endpoint for this study is grade 2–3 breast ﬁbro-
sis after radiotherapy and the secondary endpoints are other late
morbidity, local recurrence and genetic risk proﬁling for develop-
ment of late radiation morbidity. The results on these two trials
regarding late normal tissue effects will not become available for
several years, but will be able to give deﬁnitive data regarding
the effects of irradiated breast volume on normal tissue effects.
The 3D-CRT/IMRT based PBI series [32–34] have conﬂicting re-
ports on the relationship between the treated volume and NTC.
These reports have been compared by Bentzen and colleague
[52] which may explain these contradictory results. Post surgical
defect and cosmesis are important variable inﬂuencing overall cos-
mesis [53] and the mean excision cavity volume was possibly
smaller for William Beaumont group as compared to the othertwo series. Chen et. al. [34] optimised the IMRT plans with hot
spots of <110% as compared to the other two series which accepted
the hot spots of <120%. In addition, Jagsi et al. [32] used breath hold
which may have reduced the spread of planned APBI beams seen
with free breathing. Ultimately, mature data from the ongoing
Phase 3 NSABP B-39/RTOG 0413 trial will answer if an association
between breast volume irradiated in APBI and normal tissue com-
plications is real.
Other studies evaluating the relationship between volume of
breast irradiated and NTC are mainly single centre case series. A
variety of treatment modalities have been used including brachy-
therapy, IORT using low energy X-ray, 3D-CRT/IMRT. Overall, most
studies support a positive association between the boost/treat-
ment volume and NTC risks. However, this association is con-
founded by other factors including extent of surgical excision,
total delivered dose, dose fractionation, post-operative complica-
tions and brachytherapy dose inhomogeneity. Surgical excision
volume and baseline surgical cosmesis are signiﬁcant factors
affecting cosmesis [11,54–56]. A larger surgical excision would also
imply a larger brachytherapy boost volume and a larger applicator
size for IORT. It is difﬁcult to draw strong support on the indepen-
dent volume effect on NTC based on the results of these case series.
A small number of studies in the literature have suggested no
independent dose–volume relationship for breast tissue. The Fox
Chase Cancer Center series [19] with more than 3000 patients
showed no independent association between boost cut-out size
and cosmesis/breast ﬁbrosis. Only the bra cup size and electron en-
ergy were found as independent variables associated with ﬁbrosis.
This is however a retrospective series of patients treated over
38 years, with a variable boost dose of 10–18 Gy. There was no
information on the actual treated boost volume and no distinction
was made between physician and patient cosmetic score. Surgical
and radiotherapy techniques have also improved over the last four
decades, which may also affect overall cosmesis and breast ﬁbrosis.
The brachytherapy boost series with no volume–NTC correlation
[57,58] had small number of patients with fewer NTC events. It is
possible that surgical and other radio-therapeutic parameters vari-
ables were dominant in affecting NTC than a small difference in
boost volume. Studies using mammosite have also consistently
showed a lack of correlation between NTC and mammosite balloon
volume. This could be secondary to a small absolute difference in
irradiated breast volume with change in balloon ﬁll and a relatively
smaller target volume for mammosite brachytherapy as compare
to 3D-CRT [59,60].Future directions
More robust data are required to quantify the impact of volu-
metric parameter on breast NTC probability. The current PBI versus
WBI trials database with mature follow up and prospectively col-
lected dosimetric data will provide more qualitative and quantita-
tive data which may help in creating NTC analytical function in the
future. Meanwhile, efforts should be made to avoid unnecessary
treatment of normal breast tissue by optimal localisation of tu-
mour bed using implanted surgical markers and/or ultrasound
[61,62] and using conformal radiotherapy techniques with simul-
taneously integrated boost [63]. The use of image guided radio-
therapy (IGRT) with correction strategy can reduce irradiated
breast tissue during PBI and boost treatment [64], and will need
further investigation within clinical trials.
A better understanding of tissue dose–volume relationship can
be clinically exploited in high risk patients. For example, dose esca-
lation in prostate radiotherapy exploits the radiation dose–volume
principle: a small volume of rectum can receive a higher dose with
no increase in toxicity, by reducing the dose to rest of the rectal
volume using IMRT [5]. The St. George and Wollongong trial from
8 Radiation dose–volume effect on breast tissueSydney suggests that this modulation effect is also present in
breast tissue [65]. The trial randomised 688 patients with T1-
2N0-1 breast cancer between standard arm of WBI with 50 Gy in
2 Gy daily fractions (no boost) and test arm of WBI of 45 Gy in
1.8 Gy daily fractions plus a 16 Gy tumour bed boost. The overall
cosmesis was scored by a ﬁve person panel using digital photo-
graphs as excellent, good, fair and poor. 79% patients in the test
arm with boost and 68% patients in the standard arm had excel-
lent/good cosmesis (p = 0.016). The rate of moderate to severe
breast ﬁbrosis at ﬁve years was similar in both treatment arms.
These results are contrary to the current literature of worse cos-
metic outcome and higher rates of breast ﬁbrosis with additional
boost radiation. One possible explanation for these results is that
a modest dose reduction to the whole breast allowed dose escala-
tion to the tumour bed without the expected increase in normal
tissue toxicity.
This dose modulating effect on the breast is further investigated
in the IMPORT High trial [50,66] which is currently open to recruit-
ment. The trial randomises high risk patients between three
groups; standard arm: 40 Gy in 15 fractions to the whole breast
over 3 weeks with a 16 Gy in 2 Gy daily fraction sequential tumour
bed boost, Test arm 1: 36 Gy in 15 fraction to the low risk volume
of the breast, 40 Gy in 15 fractions to the index quadrant + con-
comitant tumour bed boost of 48 Gy in 15 fractions and Test arm
3: 36 Gy in 15 fractions to the low risk volume of the breast,
40 Gy in 15 fractions to the index quadrant + concomitant tumour
bed boost of 53 Gy in 15 fractions (Supplementary-Fig. 2). The trial
tests the hypothesis that decreasing the radiation dose to the
whole breast tissue by a very small amount (40 Gy to 36 Gy) and
treating an iso-effective dose to the index quadrant and tumour
bed (Arm 1), may result in less normal tissue side effects compared
to the control group. It will also test if decreasing the radiation
dose to the whole breast tissue by a very small amount allows dose
escalation to the tumour bed (area of highest risk of local recur-
rence) without an increase in normal tissue side effects (Arm 2).
Conclusions
Adjuvant breast radiotherapy reduces local recurrence and im-
proves overall survival but at a cost of increased normal tissue side
effects. This can have a signiﬁcant physical and psychological im-
pact on patients [67]. Many factors inﬂuence NTC after breast RT
including breast volume, post-surgical cosmesis, boost radiation,
chemotherapy and smoking. In addition, the current literature
seems to suggest that volumetric parameter is also important.
More direct evidence will emerge from the IMPORT LOW, Danish
Breast Cancer Co-operative Group trial and the dosimetric data col-
lected prospectively from the various Accelerated PBI trials. There
is emerging evidence to support the hypothesis that a modest dose
reduction to part of the breast facilitate dose escalation to the tu-
mour bed, and this concept will be tested further within a second
larger randomised controlled trial.
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